Core Viewpoint - Robbins LLP is urging stockholders of Smart Digital Group Limited (NASDAQ: SDM) who have incurred significant losses to contact the firm regarding a class action lawsuit filed on their behalf, focusing on allegations of market manipulation and fraudulent promotion schemes [1]. Group 1: Allegations and Legal Actions - The class action lawsuit pertains to investors who purchased SDM securities between May 5, 2025, and September 26, 2025 [1]. - Allegations include that insiders facilitated a market manipulation scheme involving misinformation on social media and impersonators posing as financial professionals [1]. - It is claimed that insiders used offshore accounts to coordinate the dumping of shares during a price inflation campaign, and that SDM's public statements failed to disclose risks related to fraudulent trading [1]. Group 2: Stock Price Impact - On September 26, 2025, SDM's stock price plummeted by 86.4%, closing at $1.85 per share after a trading halt due to volatility [1]. - The SEC suspended trading of SDM securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [1]. - NASDAQ also suspended trading in SDM securities on October 11, 2025, pending further information [1]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [1]. - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [1].

Core Viewpoint - Faruqi & Faruqi, LLP is reminding investors of F5, Inc. about the deadline for a securities class action lawsuit, which is set for February 17, 2026, due to allegations of misleading statements related to a significant security breach affecting the company's capabilities [1] Group 1: Company Overview - F5, Inc. (NASDAQ: FFIV) is facing a federal securities class action lawsuit alleging violations of federal securities laws by making false or misleading statements regarding its security capabilities [1] - The lawsuit claims that F5 was experiencing a significant security breach that impacted its ability to secure client data, which was not disclosed to investors [1] Group 2: Financial Impact - On October 27, 2025, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, largely attributed to the security breach [1] - Following the announcement, F5's stock price dropped from $290.41 per share on October 27, 2025, to $258.76 per share by October 29, 2025, marking a decline of 10.9% in just two days [1] Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action lawsuit is February 17, 2026, and any member of the class can move the court to serve as lead plaintiff [1] - Faruqi & Faruqi encourages individuals with information regarding F5's conduct, including whistleblowers and former employees, to come forward [1]

NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may ...

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO, Inc. for allegedly misleading investors about the viability of its drug candidate RGX-111, which has faced significant safety concerns and regulatory scrutiny [1]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that REGENXBIO misrepresented the safety and efficacy of RGX-111, a gene therapy for MPS I, despite knowing about serious safety issues, including the potential for CNS neoplasm [1]. - The FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor during the Phase I trial, leading to a significant drop in the company's stock price from $13.41 to $11.01, a decline of 17.8% in one day [1]. - Shareholders are encouraged to participate in the class action, with a deadline for lead plaintiff submissions set for April 14, 2026 [1]. Group 2: Company Background - REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapies that deliver functional genes to cells with genetic defects in the United States [1].

Core Insights - BioMarin Pharmaceutical (NASDAQ:BMRN) is identified as one of the 17 biotechnology stocks with over 50% upside potential, with a projected median 1-year price target of $88.29, indicating more than 47% upside from its current level [1] - Analyst sentiment is moderately bullish, with 10 out of 15 analysts rating the stock as Buy and 5 as Hold, with no Sell ratings [1] - Piper Sandler's analyst Allison Bratzel reiterated an Overweight rating on BioMarin, reducing her price target from $122 to $84, which still suggests over 40% upside potential [2] Company Overview - BioMarin Pharmaceutical specializes in developing and commercializing targeted therapies for life-threatening medical conditions and rare genetic diseases, with key products including VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME [3] - The company operates in more than 70 countries and has several drugs currently in the development stage [3]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against ICON Public Limited Company due to concerns over accounting practices and internal controls, particularly regarding revenue recognition from fiscal years 2023 to 2025 [1] Group 1: Investigation Details - The investigation is focused on whether ICON and/or its senior management violated federal securities laws or engaged in unlawful business practices [1] - ICON's Audit Committee is currently conducting an investigation into certain accounting practices and internal controls [1] - The company has indicated that it expects to report one or more material weaknesses in internal control over financial reporting [1] Group 2: Financial Impact - Following the announcement of the investigation, ICON's share price fell by $53.06, approximately 40%, from $133.14 on February 11, 2026, to close at $80.08 on the same day [1] - ICON has delayed the release of its fourth quarter and full year 2025 financial results and has withdrawn its previously issued 2025 guidance [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. for the period between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the company's drug candidate and its regulatory approval status [1]. Group 1: Lawsuit Details - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline, which led to investors suffering damages when the true information became public [5]. - Investors who purchased uniQure shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information. A lead plaintiff must file a motion by April 13, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - BellRing Brands, Inc. is facing a federal securities class action lawsuit due to allegations that the company misrepresented its sales growth and downplayed competitive pressures, leading to significant losses for investors [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased BellRing securities between November 19, 2026, and August 4, 2025, alleging that the company falsely attributed sales growth to increased consumer demand while the actual growth was due to inventory stockpiling by key customers [1]. - The company claimed that it was not experiencing significant competition and had a "competitive moat" in the ready-to-drink category, which was later contradicted by the reality of weakening demand due to competitive pressures [1]. Financial Impact - On May 6, 2025, BellRing disclosed that several key retailers had reduced their inventory levels, which was expected to negatively impact third-quarter growth, leading to a share price drop of approximately 19%, from $78.43 to $63.55 [1]. - Following the release of disappointing fiscal 3Q 2025 results on August 4, 2025, which included a narrowed sales outlook of $2.28-$2.32 billion, the share price fell by about 33%, from $53.64 to $36.18 [1].

Clear Channel Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Clear Channel Outdoor Holdings, Inc. - CCOFeb 12, 2026 11:21 AM Eastern Standard Time# Clear Channel Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Clear Channel Outdoor Holdings, Inc. - CCOShare---NEW YORK CITY & NEW ORLEANS--([BUSINESS WIRE])--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [Kahn Swick ...